SEI Investments’s ImmunityBio IBRX Stock Holding History

SEI Investments’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$344K	Hold	39,330	–	–	﹤0.01%	2803
2026 Q1	$302K	Sell	39,330 -38,705	-50%	-$265K	﹤0.01%	2824
2025 Q4	$155K	Buy	78,035 +66,226	+561%	+$150K	﹤0.01%	2961
2025 Q3	$29.1K	Hold	11,809	–	–	﹤0.01%	2805
2025 Q2	$31.2K	Hold	11,809	–	–	﹤0.01%	2771
2025 Q1	$35.5K	Buy	+11,809	New	+$35.8K	﹤0.01%	2702
2024 Q2	–	Sell	-13,772	Closed	-$74K	–	2682
2024 Q1	$74K	Buy	+13,772	New	+$62.4K	﹤0.01%	2531
2018 Q3	–	Sell	-329	Closed	-$1K	–	2909
2018 Q2	$1K	Hold	329	–	–	﹤0.01%	3468
2018 Q1	$1K	Buy	+329	New	+$1.44K	﹤0.01%	3325
2015 Q4	–	Sell	-3,743	Closed	-$43K	–	2600
2015 Q3	$43K	Buy	+3,743	New	+$81.7K	﹤0.01%	1946

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SEI Investments's IBRX Position: Q2 2026 in Review

SEI Investments held its ImmunityBio (IBRX) position steady in Q2 2026 at 39,330 shares worth $344K. The position accounts for ﹤0.01% of the portfolio, ranked #2803.

SEI Investments first reported a position in IBRX in Q3 2015 and has held it in 10 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

SEI Investments held 39,330 shares of ImmunityBio worth $344K as of Q2 2026.
SEI Investments left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #2803 holding.
SEI Investments first reported a position in ImmunityBio in Q3 2015 and has held it in 10 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.